A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J. Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds